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Abstract. For the first time a complex of L-arginine sodium salt of sulfate of cellulose acetate on 
activated carbon. To investigate the processes of sorption-desorption of  
L-arginine in a model environment. In animal experiments it was shown that granulirovannye the 
form of a combined preparation in dosages of 30 mg/kg, 70 mg/kg and 200 mg/kg exhibits a 
pronounced anti-hypertensive, endothelioprotecive and cardioprotective activity in a dosage of 
200 mg/kg. 
Keywords: L-arginine, L-NAME, water-soluble cellulose derivative, activated carbon, 
immobilized complex, endothelial dysfunction. 
 
Endothelial dysfunction is the main predictor of 
diseases of cardiovascular system, diabetes and their 
complications [1, 2, 3, 4, 5]. It was previously shown 
[6, 7, 8, 9, 10, 11], that L-arginine applied both in 
monotherapy and in combination with 
antihypertensive agents in the ADMA-(asymmetric 
dimethylarginine)-like model of L-NAME-(N
G
-nitro-
L-arginine methyl ester)-induced endothelial 
dysfunction increases effectively the activity of 
endothelial NO-synthase and the production of nitric 
oxide, and also prevents the development of 
endothelial dysfunction in experimental animals [12]. 
Currently, the main pharmaceutical form of  
L-arginine is a capsule, which upon dissolving in the 
gastric environment can affect the medical and 
biological properties of the drug. One of the 
promising methods for increasing biological activity 
is a modification of the original substance L-arginine 
with the natural polymers and the creation of new 
dosage forms based on the product of their 
interaction [13, 14]. 
Objective of this study was to obtain polymer 
complexes of L-arginine with cellulose anionic 
polyelectrolyte - cellulose acetate sulfate in the form 
of sodium salt (Na-CAS) immobilized on activated 
carbon, and to evaluate their endothelio- and 
cardioprotective activity in experimental animals 
under L-NAME-induced nitric oxide deficiency  
[15, 16, 17, 18].  
Experimental part.  
Content of the combined sulfuric acid in Na-
CAS was 27.8 wt. % combined acetic acid – 21.4  
wt. %, average molecular weight – 30∙103 g/mol.  
L-arginine was used in the form of hydrochloride. 
Complexation was carried out by mixing water 
solutions of the components at the amino acid-to-
polymer weight ratio of 5:1 to 1:5. Isolation of the 
obtained soluble complexes was carried out through 
precipitation in ethanol with further re-precipitation. 
Twice re-precipitated complex was dried in a rotary 
evaporator. L-arginine content in the complex was 
determined by UV spectroscopy with complexation with 
ninhydrin according to the procedure [19]. UV-spectra 
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were recorded with a spectrophotometer Metertech 
UV/VIS SP 8001 in quartz cuvettes 1 cm thick. 
The intrinsic viscosity of the polymer and the 
complex in aqueous solutions was determined by 
using an Ubbelohde viscometer in the 0.2 M NaCl 
solution at 25⁰С. The surface tension at the liquid-air 
boundary was measured by stalagmometric method  
Immobilization of the complex was conducted 
on AUT-MI activated carbon from an aqueous 
solutions followed by granulation and drying of the 
resulting paste. The specific Gibbs adsorption of 
arginine and arginine-polymer complex from their 
aqueous solutions on activated carbon OU-A, TH-
90G and AUT-MI was evaluated by the residual 
concentration of L-arginine in solution after 
extraction of coal [7]. 
To determine the amount of arginine, isolating 
from the resulting dosage form in the simulated 
internal environments, the pharmacopeial buffers pH 
1.2 (0.1 M HCl), pH 6.2 (phosphate buffer) and pH 
7.5 (phosphate buffer) were used.  
Experiments were performed in male albino 
Wistar rats weighing 180-200. For simulation of 
endothelial dysfunction, L-NAME was administered 
intraperitoneally at a dose of 25 mg/kg/day for seven 
consecutive days [4, 5, 7, 8, 9]. Complex of  
L-arginine with polymer immobilized on activated 
carbon was administered intragastrically by gavage 
30 minutes prior to administration of L-NAME at a 
dose of 30 mg/g, 70 mg/kg and 200 mg/kg based on 
the active substance once a day for 7 days. Intact 
animals were intragastrically administered an 
equivalent volume of saline for 7 days. On day 10 of 
the experiment, a catheter was inserted under 
anesthesia (chloral hydrate 300 mg/kg) into the left 
carotid artery to record blood pressure (BP). Bolus 
administration of pharmacological agents was into 
the femoral vein. Hemodynamic parameters: systolic 
blood pressure (SBP), diastolic blood pressure (DBP) 
and heart rate (HR) were measured continuously with 
the use of a TSD104A sensor and the МР150 
hardware and software system (BiopacSystem, Inc., 
USA). In addition to blood pressure measurements, a 
series of functional tests was performed with 
subsequent evaluation of changes in hemodynamic 
parameters (SBP, DBP, HR) in response to 
endothelium-dependent vasodilatation caused by 
intravenous administration of solution of 
acetylcholine (AC) at a dose of 40 mg/kg at the rate 
of 0.1 ml per 100 g body weight of animal (EDVD), 
as well as changes in hemodynamic parameters in 
response to the intravenous administration of sodium 
nitroprusside (NP) at a dose of 30 mg/kg at the rate of 
0.1 ml per 100 g body weight of animal [20, 21]. The 
degree of endothelial dysfunction in experimental 
animal, as well as the degree of its correction with the 
studied medications was assessed by the estimated 
coefficient of endothelial dysfunction (EDC), which 
represents the ratio of the area of a triangle above the 
BP recovery curve in response to the NP 
administration (EIVD) to the area of a triangle above 
the BP recovery curve in response to the AH 
administration (EDVD) [4, 5, 7, 8, 9]. 
Results and discussion: 
Complexation of L-arginine with Na-CAS is 
possible by electrostatic interaction of the sulfate 
groups of the polymer and protonated amine groups of 
L-arginine with the formation of an amino acid 
polymeric salt. It was found that the L-arginine with 
Na-CAS forms a soluble complex of constant 
composition upon mixing the initial components in 
any proportions. Complexation is accompanied by a 
decrease in charge density of a polyelectrolyte chain 
and, as a consequence, the transition of Na-CAS 
macromolecules to a more convolute conformation, 
which is confirmed by a decrease in the intrinsic 
viscosity of the polymer in the solution in the presence 
of L-arginine: from 0.44 to 0.32 dl/g [22]. The 
complex composition corresponds to the molar ratio of 
Na-CAS cellobiose ring to L-arginine – 1,0:1,0.  
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Figure 1.  Adsorption isotherms of L-arginine and L-
arginine -Na-SAC on activated carbons at T = 298 K.  
1 – complex L-arginine – Na-SAC on AUT-MI; 1’–  
L-arginine on AUT-MI; 2 – complex L-arginine - Na-SAC 
on ОU-А; 2’– L-arginine on ОU-А; 3 – complex  
L-arginine - Na-SAC on TH-90G;  
3’ – L-arginine on TH-90G 
 
Since the resulting complex is water-soluble, a 
water-insoluble carrier, namely, activated carbon 
(AC) was used to produce a solid dosage form. We 
may assume that the adsorption of L-arginine in AC 
occurs mainly in the micropores, since the values of 
maximum adsorption (Fig. 1) for AC with different 
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pore structures are correlated with the micropore volume (Table 1) [23].   
 
Table 1  
Maximum Gibbs adsorption value, specific surface area and pore structure characteristics of the applied  
activated carbons 
 
Coal 
Pore volume, cm
3
/g Sspec, 
m
2
/g 
G∞·10
3
  
(L-arginine), g/g 
G∞·10
3
 
(complex), g/g Vmicro Vmeso, macro  Vtotal 
AUT-MI  
(SvetlogorskKhimvolokno, JSC) 
0.38 0.18 0.56 920 320.2 340.2 
OU-A (sorbent, Perm) 0.24 0.31 0.55 750 210.1 235.1 
TH-90G (Silicarbon, Germany) 0.22 0.25 0.47 800 190.1 190.2 
 
According to the data from Fig. 1, the maximum 
adsorption of both individual and complex-bound L-
arginine (expressed as L-arginine) is typical of the 
fibrous microporous coal AUT-MI. At the same time, 
complex-bound L-arginine is adsorbed to a greater 
extent that can be associated with an increase in its 
hydrophobic property resulting from complexation. 
Experimental evidence of hydrophobic properties of 
the L-arginine-Na-CAS complex can be its surface 
activity manifesting itself on the background of 
surface-indifferent properties of L-arginine and 
surface-inactive properties of Na-CAS (Fig. 2).  
Desorption of L-arginine from the carbon carrier 
surface into pharmacopoeial buffers depends on pH. It 
was found that 10.0±0.1 wt. % of L-arginine is released 
in acidic gastric medium (pH 1.0). Further increase of 
the desorption time gives no release of L-arginine 
observed. In intestinal-simulating alkaline medium, a 
significantly higher amount of L-arginine is released 
during the same period of time – 96.3±0.5 wt. %.  
 
 
 
Figure 2.  Surface tension isotherms of aqueous solutions at T = 298 K.  
1 – Na-CAS; 2 – L-arginine; 3 – complex L-arginine-Na-CAS.  
 
The influence of L-arginine in the form of a 
complex with Na-CAS immobilized on activated 
carbon at doses of 30 mg/kg, 70 mg/kg and 200 
mg/kg on initial values of blood pressure and the 
coefficient of endothelial dysfunction was assessed in 
vivo in anesthetized rats upon modeling the  
L-NAME-induced pathology (Table 2) as compared 
to pure L-arginine [20].  
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Table 2  
The effect of new dosage form of L-arginine on hemodynamics values and EDC in modeling of L-NAME-induced 
endothelium dysfunction (M±m n=10) 
 
Groups of animals Functional test SBP, mm Hg DBP, mm Hg EDC 
Intact 
Reference 137.7±3.7 101.9±4.3 
1,1±0,1 AC 84.3±4.5 38.7±2.8 
NP 83.0±3.7 42.1±4.4 
L-NAME 
(25 mg/kg) 
 
Reference 190.3±6.7* 145.0±3.9* 
5,4±0,6* AC 110.6±5.2 82.8±6.6* 
NP 88.7±4.7 50.8±4.2 
L-NAME + L-arginine-
Na-CAS (30 mg/kg) 
Reference 180,8±8,8 141,4±9,0 
3,0±0,2**Х  AC 112,6±8,5 63,4±7,3 
NP 89,4±4,3 57,6±5,8 
L-NAME + L-arginine 
(30 mg/kg) 
Reference 188,5 ± 14,8* 137,3 ± 9,9* 
3,6±0,3** AC 85,3±5,0** 53,1±3,4** 
NP 97,0±6,2 66,7±4,3 
L-NAME + L-arginine-
Na-CAS (70 мг/кг) 
Reference 176,2 ± 6,0**Х 130,7±8,1** 
2,3±0,2**Х AC 98,7±8,7 53,7±9,8 
NP 96,5±11,5 50,7±3,4 
L-NAME+ L-arginine 
(70 мг/кг) 
Reference 195,2±13,5 136,5 ± 4,8** 
2,7±0,1** AC 116,8 ± 4,6* 85,1 ± 4,6* 
NP 100,3 ± 6,7 58,9 ± 7,8** 
L-NAME + L-arginine-
Na-CAS (200 мг/кг) 
Reference 141,4±12,2**Х 118,7±9,8** 
1,9±0,1**Х AC 86,3±10,3 47,1±8,7** 
NP 94,6±7,1 42,3±6,4 
L-NAME + L-arginine 
(200 мг/кг) 
Reference 177,6 ± 9,6* 120,1 ± 6,4* 
2,5±0,1** AC 85,3 ± 5,0 51,3 ± 2,5 
NP 102,0 ±3,8 44,1 ± 2,9 
 
Note: *– at p<0.05 as compared to control animals; **– at p<0.05 as compared to group receiving L-NAME; Х – at 
p<0.05 as compared to group receiving to pure L-arginine in the appropriate dose 
 
From table 2 that in all dosages of the new drug 
forms of L-arginine, the values of EDC were more 
close to the level of intact animals in comparison 
with pure form of L-arginine, additionally, a new 
pharmaceutical form of L-arginine at a dose of  
200 mg/kg in the largest extent prevented the 
development of severe systolic hypertension. 
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Table 3  
The effect of new dosage form of L-arginine on the left ventricle of rats’ heart contractility (M±mn=10) 
 
Groups of animals Initial LVP, mm Hg Adrenoreactivity, mm Hg 
Myocardial reserve level, 
(%) 
Intact 108,6±4,3 199,2±8,3 83,6±4,2 
L-NAME 
(25 mg/kg) 
167,8±5,6* 247,3±4,8* 66,0±3,4* 
L-NAME + L-arginine-
Na-CAS (30 mg/kg) 
131,9±11,2**
Х 
222,7±16,6**Х  68,5±6,3* 
L-NAME + L-arginine  
(30 mg/kg) 
173,7±37,6* 253,2±10,8* 69,0±6,1* 
L-NAME + L-arginine-
Na-CAS (70 мг/кг) 
136,0±5,0**Х 229,6±2,2**Х 83,1±3,7**Х 
L-NAME+ L-arginine 
(70 мг/кг) 
160,0±29,8* 250,8±12,3* 70,5±5,8* 
L-NAME + L-arginine-
Na-CAS (200 мг/кг) 
127,9±11,5**Х  201,6±12,3**Х  84,0±4,7** 
L-NAME + L-arginine 
(200 мг/кг) 
142,1±8,3** 223,5±7,3** 84,3±4,5** 
 
Note: *- at p<0.05 as compared to control animals; **- at p<0.05 as compared to group receiving L-NAME; 
Х
 - at 
p<0.05 as compared to group receiving to pure L-arginine in the appropriate dose. 
 
When carrying out a load of heart samples the 
initial contractility of the left ventricle in animals 
treated with L-NAME were significantly higher than 
the intact (table 3). Preparations of L-arginine 
immobilized in the form of significantly better 
prevented the increase in baseline left ventricular 
pressure, which indicates best negative inotropic 
action of this form of L-arginine in the simulation of 
hyperkinetic disorders of the myocardium [241]. 
The results of the study of the functional state of 
the myocardium during exercise testing revealed the 
benefits of cardioprotective action of a new form of 
L-arginine in all doses, expressed in preventing the 
increase in adrenoreactivity. A statistically significant 
advantage in preventing the fall of LVP the tests on 
the load resistance in the conventional form revealed 
only by the introduction of a new form of L-arginine 
at a dose of 200 mg/kg. L-arginine at doses of 30 
mg/kg and 70 mg/kg of both forms, showed 
cardioprotective effect in lesser degree. 
Thus, L-arginine in the form of a complex with 
Na- Na-CAS immobilized on activated carbon, at 
doses of 30 mg/kg, 70 mg/kg and 200 mg/kg showing 
the most pronounced antihypertensive and 
endothelioprotective activity. The most pronounced 
cardioprotective activity showed L-arginine in the 
form of a complex with Na-CAS, immobilized on 
charcoal, in the dose of 200 mg/kg. 
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